# Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity

> **NCT00120055** · PHASE4 · COMPLETED · sponsor: **University of Oslo School of Pharmacy**

## Conditions studied

- Myopathy

## Interventions

- **DRUG:** Atorvastatin (Lipitor)

## Key facts

- **NCT ID:** NCT00120055
- **Lead sponsor:** University of Oslo School of Pharmacy
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** — (—)
- **Last updated:** 2014-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00120055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00120055, "Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00120055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*